South Shore Hospital gets $5m gift Boston Globe Tue, 24 Jan 2012 14:00 PM PST South Shore Hospital has received a $5 million gift that it plans to use to boost cancer care, orthopedics, home care, and to help build a 60-bed expansion. The gift from the McKim Family Foundation is the largest in the hospitalâs 90-year history. Braintree native Alan McKim founded the environmental cleanup company Clean Harbors in 1980. McKim said the hospital touches hundreds of lives in the ... | Donald G. âPopsâ Bango, Aug. 19, 1941-Jan. 23, 2012 The Sandusky Register Tue, 24 Jan 2012 13:57 PM PST Donald G. âPopsâ Bango, 70, of Sandusky, went home to a better place, Monday, Jan. 23, 2012, in Firelands Regional Medical Center, after a brief battle with cancer. read more | Caregiving Burden, Stress, and Health Effects Among Family Caregivers of Adult Cancer Patients [Grand Rounds] Journal of the American Medical Association Tue, 24 Jan 2012 13:57 PM PST Unlike professional caregivers such as physicians and nurses, informal caregivers, typically family members or friends, provide care to individuals with a variety of conditions including advanced age, dementia, and cancer. This experience is commonly perceived as a chronic stressor, and caregivers often experience negative psychological, behavioral, and physiological effects on their daily lives ... | Unwrapping the Implications of BRCA1 and BRCA2 Mutations in Ovarian Cancer [Editorial] Journal of the American Medical Association Tue, 24 Jan 2012 13:57 PM PST Three large studies have demonstrated improved survival in BRCA -associated ovarian cancers compared with sporadic ovarian cancers. 1 , 2 , 3 These trials have combined BRCA1 and BRCA2 mutation carriers because of the relative rarity of BRCA1 and BRCA2 mutations, which only account for approximately 10% and 5% of unselected cases of serous ovarian cancer, respectively. | BRCA1 and BRCA2 Mutations in Ovarian Cancer [Letters] Journal of the American Medical Association Tue, 24 Jan 2012 13:57 PM PST To the Editor: Dr Yang and colleagues found significantly better progression-free survival rates in women with ovarian cancer and BRCA2 mutations compared with BRCA1 mutations or wild-type BRCA . 1 In addition, they reported that BRCA2 mutations were associated with a 100% primary chemotherapy sensitivity rate compared with 82% for BRCA wild-type and 80% for BRCA1- mutated cases, suggesting an ... | BRCA1 and BRCA2 Mutations in Ovarian Cancer--Reply [Letters] Journal of the American Medical Association Tue, 24 Jan 2012 13:56 PM PST In Reply: Drs Buerkle and Tempfer asked whether differences in progression-free survival and primary chemotherapy response between BRCA1 - and BRCA2 -mutated cases could be the result of unbalanced distribution of disease stages and extent of cytoreduction. | | |
|